Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

13.34 -0.53 (-3.86%)

Streaming Delayed Price Updated: 3:13 PM EDT, May 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022 ↗

September 01, 2022

Upgrades

Via Benzinga

Expert Ratings for Intellia Therapeutics ↗

September 01, 2022

Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Where Intellia Therapeutics Stands With Analysts ↗

September 01, 2022

Over the past 3 months, 5 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

August 26, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Expert Ratings for Intellia Therapeutics ↗

August 05, 2022

Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings:

Via Benzinga

Recap: Intellia Therapeutics Q2 Earnings ↗

August 04, 2022

Intellia Therapeutics (NASDAQ:NTLA) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday ↗

August 24, 2022

Gainers

Via Benzinga

Macy's, Palo Alto Networks And Other Big Gainers From Tuesday ↗

August 24, 2022

U.S. stocks closed mostly lower with the Dow Jones dropping more than 150 points on Tuesday. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis ↗

June 24, 2022

Via Benzinga

BMO Initiates Coverage On This Gene Editing Spearhead ↗

June 17, 2022

Via Benzinga

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher ↗

August 17, 2022

These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up.

Via InvestorPlace

7 Stock Price Predictions That Are Actually Worth Listening To ↗

August 12, 2022

Investors may take advantage of analyst stock price predictions beyond the recent share price to discover promising investments.

Via InvestorPlace

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗

August 05, 2022

Shares of Pfizer's rumored takeover target have rocketed for two days running.

Via Investor's Business Daily

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug ↗

August 05, 2022

The company will compete with Pfizer, which already has an approved drug.

Via Investor's Business Daily

Clorox, Crocs And Some Other Big Stocks Moving Lower On Thursday ↗

August 04, 2022

AMTD Digital Inc. (NYSE: HKD) dipped 43.6% to $620.00 on possible profit taking after the stock surged over the last few trading days.

Via Benzinga

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned ↗

August 04, 2022

Intellia is backing off the higher dose of a gene-editing drug in cardiomyopathy patients.

Via Investor's Business Daily

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today? ↗

August 03, 2022

Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.

Via InvestorPlace

7 Cathie Wood Stocks Trading at a Discount Right Now ↗

July 26, 2022

These 7 Cathie Wood stocks are the best choices to buy in June. COIN, FATE, NTLA, MELI, TDOC, TSLA, and ZM can make excellent investments.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 20, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

The 3 Leaders of the Gene Editing Revolution ↗

July 08, 2022

There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.

Via InvestorPlace

7 Moonshot Investments Upending a $10 Trillion Industry ↗

July 08, 2022

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.

Via InvestorPlace

Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names ↗

July 06, 2022

Biotech stocks continued going gangbusters Wednesday. Here's why, experts say.

Via Investor's Business Daily

Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying ↗

July 06, 2022

Biotech stocks continued going gangbusters Wednesday. Here's why, experts say.

Via Investor's Business Daily

Analyst Ratings for Intellia Therapeutics ↗

June 16, 2022

Over the past 3 months, 7 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022 ↗

June 16, 2022

Upgrades

Via Benzinga

Analyst Ratings for Intellia Therapeutics ↗

May 24, 2022

Over the past 3 months, 8 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

May 09, 2022

Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading.

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Preview For Intellia Therapeutics ↗

May 04, 2022

Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.